Home
ACE Reports
All Specialties All Specialties All Specialties Arthroplasty Arthroplasty Arthroplasty Evidence Based Medicine Evidence Based Medicine Evidence Based Medicine Foot & Ankle Foot & Ankle Foot & Ankle General Orthopaedics General Orthopaedics General Orthopaedics Hand & Wrist Hand & Wrist Hand & Wrist Metabolic Disorders Metabolic Disorders Metabolic Disorders Osteoarthritis Osteoarthritis Osteoarthritis Pediatric Orthopaedics Pediatric Orthopaedics Pediatric Orthopaedics Peri-Operative Peri-Operative Peri-Operative Physical Therapy & Rehab Physical Therapy & Rehab Physio & Rehab Shoulder & Elbow Shoulder & Elbow Shoulder & Elbow Spine Spine Spine Sports Medicine Sports Medicine Sports Medicine Trauma Trauma Trauma Tumour Tumour Tumour Author Interviews Author Interviews Author Interview Conference Report Conference Report Conference Reports
Original Content
News
Multimedia
About
Search
Home
ACE Reports
Arthroplasty Evidence Based Medicine Foot & Ankle General Orthopaedics Hand & Wrist Metabolic Disorders Osteoarthritis Pediatric Orthopaedics Peri-Operative Physical Therapy & Rehab Shoulder & Elbow Spine Sports Medicine Trauma Tumour Author Interviews Conference Report
Original Content
News
Multimedia
About
Search
Previous Ace Report Bioactive glass and autogenous bone as bone substitute material in tibial plateau fracture Next Ace Report Bioactive glass and autogenous bone as bone substitute material in tibial plateau fracture
Ace Report Cover
Arthroplasty
Apixaban reduces major bleeding and is non-inferior when compared to enoxaparin for TKA
Reprints
Cite This
Reprints
Cite This
AceReport Image
Arthroplasty
Apixaban reduces major bleeding and is non-inferior when compared to enoxaparin for TKA
Thromb Haemost. 2011 Feb;105(2):245-53
Contributing Authors

J Huang Y Cao C Liao L Wu F Gao

Data from 3 randomized-controlled trials (7337 individuals) was analyzed to evaluate the efficacy of apixaban in the treatment of TKA complications of venous thromboemolisms (VTE) including deep-vein thrombosis (DVT) and pulmonary embolism (PE), when compared against enoxaparin. Complication incidence was analyzed, along with safety endpoints. The results of the meta-analysis demonstrated that apixaban performed comparably to enoxaparin with advantages in DVT incidence and reduction of major-bleeding.

Unlock the full article

Get unlimited access to OrthoEvidence with a free trial
Start Trial

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or continue reading this full article
Register Now
AskOE
Search
Close Search Window
Welcome Back!
Forgot Password?
Create an Account

Account will be affiliated with

OR
Forgot Password?
OR
Check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see the email, please check your spam or junk folder.

For further assistance, contact our support team.

Cite this Ace Report

OrthoEvidence. Apixaban reduces major bleeding and is non-inferior when compared to enoxaparin for TKA. ACE Report. 2014;4(3):77. Available from: https://myorthoevidence.com/AceReport/Report/

Copy Citation
Share this Ace Report